Compass Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Compass Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.4 times its market value (net cash). Higher than 92% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-1,359.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-49.1×Operating cash was negative last year, while some debt falls due within a year.
Lower than 73% of Healthcare companies in United States.
Cash Cushion Ratio
1.4× cashCash, after subtracting all debt, is 1.4 times its market value (net cash).
Higher than 92% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Compass Therapeutics, Inc. made a loss over the last year. Compass Therapeutics, Inc. owes $0.13 for every $1 it owns. Compass Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCompass Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.87The share price is 0.87 times Compass Therapeutics, Inc.'s book value per share, lower than 82% of Healthcare companies in United States.
Market cap
$144 MThe total market value of all of Compass Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$166 MWhat Compass Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.92Net worth divided by the number of shares. The share price of $0.80 is 0.9 times this, which is the P/B above.
Return on equity (ROE)
-56.7%Compass Therapeutics, Inc. lost 56.7% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
Owes vs Owns
0.13×Compass Therapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NoneCompass Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossCompass Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashCompass Therapeutics, Inc. held $199 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Compass Therapeutics, Inc.: $144 M ÷ $166 M (30 Jun 2026) = 0.9.
What is Compass Therapeutics, Inc.'s return on equity?
Compass Therapeutics, Inc. lost 56.7% of its shareholders' money over the last year, lower than 55% of Healthcare companies in United States.
How much does Compass Therapeutics, Inc. owe compared with what it owns?
Compass Therapeutics, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does Compass Therapeutics, Inc. pay a dividend?
No. Compass Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.